Omnicell (OC9) Stock Price & Analysis
OC9 Stock Chart & Stats
- Day’s Range
- EUR 32.60 - EUR 33.00
- 52-Week Range
- EUR 27.40 - EUR 43.80
- Previous Close
- EUR 32.20
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 1.49B
- Enterprise Value
- EUR 1.43B
- Total Cash (Recent Filing)
- EUR 314.86M
- Total Debt (Recent Filing)
- EUR 189.67M
- Price to Earnings (P/E)
- 37.3
- Beta
- 0.14
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.38
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Strong operating and free cash flow indicates that recent earnings are supported by real cash generation, giving Omnicell greater flexibility to fund product development, customer deployments, and debt reduction while improving resilience through the next several quarters.
Lower Leverage
Substantially lower leverage strengthens the balance sheet and reduces financial risk, leaving more capacity to absorb uneven hospital spending, invest in cloud and automation offerings, and pursue customer growth without relying as heavily on external financing.
Platform And Pipeline Expansion
A growing and maturing pipeline, combined with customer interest in Titan XT and OmniSphere, supports a broader platform opportunity beyond hardware replacement. Integrated workflow, visibility, and workforce tools could deepen the installed base and recurring revenue over time.
Bears Say
Weak And Volatile Revenue Trend
The sharp TTM revenue decline and historically uneven top-line performance indicate that demand conversion remains inconsistent. This can limit operating leverage, complicate planning, and make sustained profitability improvement dependent on a more reliable refresh and implementation cycle.
Delayed Bookings Conversion
Back-end-weighted bookings and lengthy conversion periods defer revenue recognition and make near-term results sensitive to customer contracting and implementation schedules. The delay can create quarter-to-quarter variability even when pipeline activity and long-term demand remain constructive.
Persistent Component Cost Pressure
Ongoing memory and related component cost inflation can pressure gross margins and offset gains from cost efficiency or favorable product mix. If sustained, the headwind may reduce the profitability contribution from hardware deployments while pricing and customer adoption adjust.
OC9 FAQ
What was Omnicell’s price range in the past 12 months?
What is Omnicell’s market cap?
When is Omnicell’s upcoming earnings report date?
How were Omnicell’s earnings last quarter?
Is Omnicell overvalued?
Does Omnicell pay dividends?
What is Omnicell’s EPS estimate?
How many shares outstanding does Omnicell have?
What happened to Omnicell’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Omnicell?
What is the TipRanks Smart Score and how is it calculated?
Omnicell Stock Smart Score
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Randall A. Lipps
- Employees
- 3,580
- Website
- www.omnicell.com
- Address
- 4220 North Freeway, Fort Worth, TX, 76137, US
Omnicell (OC9) Earnings & Revenues
OC9 Company Deck
OC9 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. The company exceeded third-quarter revenue and EBITDA guidance, raised full-year EBITDA and EPS guidance, reported growing and increasingly mature pipeline activity, and highlighted customer validation for Titan XT and OmniSphere. The main challenges were timing variability in back-end-weighted bookings, modest near-term top-line growth, lower fourth-quarter revenue guidance, memory-cost pressure, a modest 340B-related ARR impact, and the multi-year timeline for OmniSphere monetization. The positive operating results, strategic progress, and pipeline commentary significantly outweighed the stated challenges.
View all DE:OC9 earnings summariesOC9 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 9 | 0 | 3 |
